blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3949968

EP3949968 - METHODS OF TREATING CANCER USING 3-(4-((4-(MORPHOLINOMETHYL)BENZYL)OXY)-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  31.01.2025
Database last updated on 11.04.2026
FormerRequest for examination was made
Status updated on  12.08.2022
FormerThe application has been published
Status updated on  07.01.2022
Most recent event   Tooltip10.12.2025Change - representative 
Applicant(s)For all designated states
Celgene Corporation
Route 206 & Province Line Road
Princeton, NJ 08543 / US
[2024/14]
Former [2022/06]For all designated states
Celgene Corporation
86 Morris Avenue
Summit, NJ 07901 / US
Inventor(s)01 / SCHAFER, Peter, H.
Belle Mead, 08502 / US
02 / GANDHI, Anita
Bernardsville, 07924 / US
 [2022/06]
Representative(s)Jones Day
Gewürzmühlstr. 11
80538 München / DE
[N/P]
Former [2022/06]Jones Day
Rechtsanwälte, Attorneys-at-Law, Patentanwälte
Prinzregentenstrasse 11
80538 München / DE
Application number, filing date21177385.808.08.2013
[2022/06]
Priority number, dateUS201261681447P09.08.2012         Original published format: US 201261681447 P
US201261722727P05.11.2012         Original published format: US 201261722727 P
[2022/06]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3949968
Date:09.02.2022
Language:EN
[2022/06]
Search report(s)(Supplementary) European search report - dispatched on:EP10.01.2022
ClassificationIPC:A61K31/5377, A61K45/06, A61P35/00, A61P35/02, A61P43/00
[2022/06]
CPC:
A61K31/5377 (EP,IL,KR,US); A61K31/573 (IL,US); A61K39/395 (IL,KR,US);
A61K45/06 (EP,IL,US); A61K9/0053 (IL,US); A61K9/48 (IL,US);
A61P35/00 (EP,IL); A61P35/02 (EP,IL); A61P43/00 (EP,IL);
C07D413/14 (IL,KR); G01N33/50 (IL,KR) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/37]
Former [2022/06]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:VERFAHREN ZUR KREBSBEHANDLUNG MIT (3-(4-(4-(MORPHOLINOMETHYL)BENZYL)OXY-)1-OXOISOINDOLIN-2-YL-)PIPERIDIN-2,6-DION[2022/06]
English:METHODS OF TREATING CANCER USING 3-(4-((4-(MORPHOLINOMETHYL)BENZYL)OXY)-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE[2022/06]
French:PROCÉDÉS DE TRAITEMENT DU CANCER À L'AIDE DE 3-(4-((4-(MORPHOLINOMÉTHYL)BENZYL)OXY)-1-OXO-ISO-INDOLIN-2-YL)PIPÉRIDINE-2,6-DIONE[2022/06]
Examination procedure08.08.2022Amendment by applicant (claims and/or description)
08.08.2022Examination requested  [2022/37]
08.08.2022Date on which the examining division has become responsible
30.01.2025Despatch of a communication from the examining division (Time limit: M06)
16.07.2025Reply to a communication from the examining division
Parent application(s)   TooltipEP13751007.9  / EP2882442
Fees paidRenewal fee
02.06.2021Renewal fee patent year 03
02.06.2021Renewal fee patent year 04
02.06.2021Renewal fee patent year 05
02.06.2021Renewal fee patent year 06
02.06.2021Renewal fee patent year 07
02.06.2021Renewal fee patent year 08
02.06.2021Renewal fee patent year 09
15.07.2022Renewal fee patent year 10
05.07.2023Renewal fee patent year 11
04.07.2024Renewal fee patent year 12
03.07.2025Renewal fee patent year 13
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[YD] US2011196150  (MAN HON-WAH et al.)
 [XY] WO2011112933  (CELGENE CORP et al.)
 [Y]   NAUGLER W E ET AL: "NF-@kB and cancer-identifying targets and mechanisms", CURRENT OPINION IN GENETICS & DEVELOPMENT, CURRENT BIOLOGY LTD, XX, vol. 18, no. 1, 1 February 2008 (2008-02-01), pages 19 - 26, XP022673190, ISSN: 0959-437X, [retrieved on 20080424], DOI: 10.1016/J.GDE.2008.01.020

DOI:   http://dx.doi.org/10.1016/j.gde.2008.01.020
by applicantUS201261681447
 US201261722727
 US7468363
 US7393862
 US60380842
 US2008051379
 WO2010137547
 US2011196150
 WO02088171
 WO2006055689
 WO0232925
 WO2005037989
 US2003133939
 US2005238646
 US5391485
 US5393870
 US5229496
 US4810643
 US4999291
 US5528823
 US5580755
 US7498171
 US3845770
 US3916899
 US3536809
 US3598123
 US4008719
 US5674533
 US5059595
 US5591767
 US5120548
 US5073543
 US5639476
 US5354556
 US5733566
 US5134127
   ROITT, I.BROSTOFF, JKALE, D.: "Immunology", 1993, MOSBY, pages: 17.1 - 17.12
   JEMAL A ET AL., CA CANCER J CLIN, vol. 57, no. 1, 2007, pages 43 - 66
   CLARKE C A ET AL., CANCER, vol. 94, no. 7, 2002, pages 2015 - 2023
   K. STAHNKE ET AL., BLOOD, vol. 98, 2001, pages 3066 - 3073
   D. KIM ET AL., JOURNAL OF CLINICAL ONCOLOGY, 2007 ASCO ANNUAL MEETING PROCEEDINGS, vol. 25, no. 18S, 20 June 2007 (2007-06-20), pages 8082
   "The Merck Manual", 1999, pages: 949 - 952
   "Cancer: Principles & Practice of Oncology", 1989, pages: 1843 - 1847
   CERNY T ET AL., ANN ONCOL, vol. 13, no. 4, 2002, pages 211 - 216
   M. AKLILU ET AL., ANNALS OF ONCOLOGY, vol. 15, 2004, pages 1109 - 1114
   JENNIFER H. ANOLIK ET AL., CLINICAL IMMUNOLOGY, vol. 122, no. 2, February 2007 (2007-02-01), pages 139 - 145
   CAIRNS, R.A. ET AL., NATURE REV., vol. 11, 2011, pages 85 - 95
   SHACKELFORD, D.B.SHAW, R.J., NATURE REV. CANCER, vol. 9, 2009, pages 563 - 575
   MARDIS, E.R. ET AL., N. ENGL. J. MED., vol. 361, 2009, pages 1058 - 1066
   PARSONS, D.W. ET AL., SCIENCE, vol. 321, 2008, pages 1807 - 1812
   STOCKDALE: "Medicine", vol. 3, 1998
   HIGGINS, J.J. ET AL., NEUROLOGY, vol. 63, 2004, pages 1927 - 1931
   JO, S. ET AL., J. NEUROCHEM, vol. 94, 2005, pages 1212 - 1224
   HOHBERGER B. ET AL., FEBS LETT, vol. 583, 2009, pages 633 - 637
   ANGERS S. ET AL., NATURE, vol. 443, 2006, pages 590 - 593
   ITO, T. ET AL.: "Identification of a primary target of thalidomide teratogenicity", SCIENCE, vol. 327, 2010, pages 1345 - 1350, XP055062167, DOI: 10.1126/science.1177319

DOI:   http://dx.doi.org/10.1126/science.1177319
   JACOB ET AL., AUTOIMMUNITY, vol. 43, no. 1, 2010, pages 84 - 97
   JOURDAN ET AL., BLOOD, vol. 114, no. 10, 2009, pages 5173 - 5181
   RALLIES ET AL., IMMUNITY, vol. 26, no. 5, 2007, pages 555 - 566
   LENZ ET AL., N. ENGL. J. MED., vol. 362, 2010, pages 1417 - 1429
   CICHY ET AL., JOURNAL OF CELL BIOLOGY, vol. 161, no. 5, 2003, pages 839 - 843
   BRELOER ET AL., TRENDS IN IMMUNOLOGY, vol. 29, no. 4, 2008, pages 186 - 194
   OWCZARCZYK ET AL., SCIENCE TRANSLATIONAL MEDICINE, vol. 3, no. 101, 2011, pages 92
   HANS ET AL., BLOOD, vol. 103, 2004, pages 275 - 282
   "Remington: The Science and Practice of Pharmacy", 2005, THE PHARMACEUTICAL PRESS AND THE AMERICAN PHARMACEUTICAL ASSOCIATION
   "Handbook of Pharmaceutical Additives", 2007, GOWER PUBLISHING COMPANY
   "Pharmaceutical Preformulation and Formulation", 2004, CRC PRESS LLC
   JENS T. CARSTENSEN: "Burger's Medicinal Chemistry and Drug Discovery", vol. 172-178, 1995, MARCEL DEKKER, pages: 379 - 982
   "Introduction to Pharmaceutical Dosage Forms", 1985, LEA & FEBIGER
   THERASSE ET AL., J. NATL. CANCER INST, vol. 92, 2000, pages 205 - 16
   JACQUES, J. ET AL.: "Enantiomers, Racemates and Resolutions", 1981, WILEY-INTERSCIENCE
   WILEN, S. H. ET AL., TETRAHEDRON, vol. 33, 1977, pages 2725
   ELIEL, E. L.: "Stereochemistry of Carbon Compounds", 1962, MCGRAW-HILL
   WILEN, S. H.: "Tables of Resolving Agents and Optical Resolutions", 1972, UNIV. OF NOTRE DAME PRESS, pages: 268
   PENICHET, M.L.MORRISON, S.L., J. IMMUNOL. METHODS, vol. 248, 2001, pages 91 - 101
   EMENS, L.A. ET AL., CURR. OPINION MOL. THER., vol. 3, no. 1, 2001, pages 77 - 84
   "Response Evaluation Criteria in Solid Tumors (RECIST) Guidelines", JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 92, no. 3, 2000, pages 205 - 216
   "Remington's Pharmaceutical Sciences", 1980, MACK PUBLISHING
   ELEFTHERAKIS-PAPAPIAKOVOU ET AL., LEUK LYMPHOMA, vol. 52, no. 12, 2011, pages 2299 - 2303
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.